Home  /  Resource Library  /  Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression

Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression

Study investigated the efficacy of ibrutinib for treatment of relapsed Hodgkin lymphoma.